Cost of Chronic Hepatitis B Infection in the United States
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
GOALS: To estimate the direct medical costs associated with chronic hepatitis B (CHB) infection in the United States. BACKGROUND: Approximately 240,000 new cases of hepatitis B infection occur annually in the United States. There are estimated to be 1.25 million sufferers of CHB in the United States. However, the economic impact of these infections has not been well studied. STUDY: We conducted a retrospective cohort analysis using administrative healthcare claims data to estimate costs for six health states associated with CHB infection. The six states were as follows: 1) CHB, 2) compensated cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5) transplant care >12 months following transplant, and 6) hepatocellular carcinoma. Patients in each health state were identified using diagnostic and procedure codes, and their utilization was tracked during their time in that health state. To estimate costs, we used reimbursed amounts and adjusted to year US 2000 dollars. RESULTS: Average annual costs for patients in each health state were as follows: CHB, US 761 dollars; compensated cirrhosis, US 227 dollars; decompensated cirrhosis, US 11,459 dollars; liver transplant, US 86,552 dollars; transplant care >12 months following transplant, US 12,560 dollars; and hepatocellular carcinoma, US 7,533 dollars. Medications contributed the largest proportion of costs in CHB and compensated cirrhosis disease states, while hospitalizations were the largest cost component in the other health states. CONCLUSIONS: This analysis provides estimates of the annual costs of complications of hepatitis B infection in the United States. The most progressive health states were associated with significantly higher costs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Average annual health care costs for patients infected with Hepatitis B are $1,814 for chronic hepatitis B and $27,316 for decompensated cirrhosis (Lee et al., 2004).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Lee, Veenstra, Iloeje, & Sullivan, 2004
In the citing paper
“Average annual health care costs for patients infected with Hepatitis B are $1,814 for chronic hepatitis B and $27,316 for decompensated cirrhosis (Lee et al., 2004).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Lee, Veenstra, Iloeje, & Sullivan, 2004
Citations
Cites
Coleman, P. J., McQuillan, G. M., Moyer, L. A., Lambert, S. B., & Margolis, H. S. (1998) · The Journal of Infectious Diseases · doi:10.1086/515696 · Cited by 143 · cited 1×
“(J Clin Gastroenterol 2004;38:S144–S147) In the United States, estimates of the incidence of hepatitis B virus (HBV) infections from the National Health and Nutrition Examination Survey indicate that there were approximately 240,000 new infections annually between 1988 and 1994.(1) Chronic hepatitis B (CHB) infection…”
BackgroundEconomic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000)
Beutels, P. (2001) · Health Economics · doi:10.1002/hec.625 · Cited by 122 · cited 1×
“Most studies have evaluated the cost-effectiveness of treatment interventions(5,6) or vaccination programs.(7) Crowley et al provided estimates of the annual costs associated with various health states of CHB in their economic evaluation of lamivudine.”
BackgroundAggarwal, R., Ghoshal, U. C., & Naik, S. R. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00382-3 · Cited by 82
Crowley, S. J., Tognarini, D. P., Desmond, P. V., LEES, M., & Saal, G. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02673.x · Cited by 49 · cited 1×
“Crowley et al provided estimates of the annual costs associated with various health states of CHB in their economic evaluation of lamivudine.(8) Their estimates in Australian dollars (A$) were: CHB, A$726; compensated cirrhosis, A$2,989; decompensated cirrhosis, A$13,647; and hepatocellular carcinoma, A$14,111.”
BackgroundBrooks, E. A., Lacey, L. F., Payne, S. L., & Miller, D. W. (2001) · PubMed · Cited by 36
Autonomic and sensory nerve dysfunction in patients with Wilson disease
Horvath, A., Keresztes, K., Folhoffer, A., Hegedüs, D., Lakatos, P. L., Dunkel, K., Kempler, P., & Szalay, F. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)80107-1 · Cited by 1
Research works printed but not linked: 1
- Brooks, 2001, Am J Manag Care, 7, 677
Cited by
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
(2010) · National Academies Press eBooks · doi:10.17226/12793 · Cited by 245
Lai, C.-L., & Yuen, M.-F. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00010 · Cited by 196
“Finally, the cost of prolonged treatment should be balanced against the substantially higher medical cost incurred when the disease progresses from chronic hepatitis to compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma, or when it progresses so far that liver transplantation is needed (25).”
Levy, A. R., Kowdley, K. V., Iloeje, U., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N., & Briggs, A. H. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00297.x · Cited by 161
Self-citationThe current economic burden of cirrhosis.
Neff, G. W., Duncan, C. W., & Schiff, E. R. (2011) · Europe PMC (PubMed Central) · Cited by 149
Clinical, economic, and humanistic burden of needlestick injuries in healthcare workers
Cooke, C. E., & Stephens, J. (2017) · Medical Devices Evidence and Research · doi:10.2147/mder.s140846 · Cited by 141
Metadata
- Authors
- Lee, T. A., Veenstra, D. L., Iloeje, U. H., & Sullivan, S. D.
- Affiliations
- Northwestern University (US)
- University of Washington (US)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Lee, Todd A.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2004-11
- Volume
- 38
- Issue
- 10 Suppl 3
- Pages
- S144-S147
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2011794322
- Cited by
- 57
- References
- 6
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2020: 3 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- chronic hepatitis B, direct medical costs, liver cirrhosis, decompensated cirrhosis, liver transplantation, transplant care, hepatocellular carcinoma, hospital costs, drug costs, economic burden of disease
- MeSH terms
- Costs and Cost Analysis, Humans, Middle Aged, Retrospective Studies, United States, Cohort Studies, Health Care Costs, Hepatitis B, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost of Chronic Hepatitis B Infection in the United States. https://app.cochat.ai/papers/10.1097/00004836-200411003-00005
- The paper
- Lee, T. A., Veenstra, D. L., Iloeje, U. H., & Sullivan, S. D. (2004). Cost of Chronic Hepatitis B Infection in the United States. Journal of Clinical Gastroenterology. https://doi.org/10.1097/00004836-200411003-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.